European Artificial Intelligence Innovation Summit (exl)

The implementation, data privacy, and operational challenges facing life science and healthcare professionals dedicated to integrating AI into their organization vastly differ by therapeutic area and patient population, size of the organization, and the number of resources available to them. Cookie-cutter solutions cannot address the unique challenges faced by a company. It is critical that the education available to these professionals meets the varying needs of the industry. As such, ExL Events has expanded its Artificial Intelligence conference series to now introduce the European Artificial Intelligence Innovation Summit. Through keynotes, panel discussions, and case studies, the executive speaking faculty provides key insights into the ethical standards of AI; explores the realistic steps to achieve successful AI execution; defines the regulatory boundaries and limitations; reviews the necessary metrics to measure the success and efficacy of the AI system; and examines case studies on industry vertical use. Dr. Alfa is Vice President, Discovery, and Product at Recursion Pharmaceuticals (recursionpharma.com), an AI-enabled drug discovery company combining state-of-the-art machine learning with automated cell biology.